Cellceutix is a clinical stage biopharmaceutical company focused on the development of a pipeline of small molecule drugs to treat unmet medical conditions, including cancers and autoimmune diseases. The company’s flagship compound, Kevetrin, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers that have proven resistant to current cancer therapies.
In more than 50% of all human cancers, p53 is limited in its anti-tumor activities by mutations in the protein itself. Currently, there are more than 10 million people with tumors that have inactivated p53 and a similar number have p53 pathways that are partially abrogated. This has left cancer researchers with the task of searching for therapies that could restore the protein’s protective function. Kevetrin appears to do so most of the time.
The company reported today that it has been advised that the clinical trials for its novel anti-cancer drug candidate, Kevetrin, will be going active this week. The trials are being conducted at Harvard Cancer Centers Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Both centers are ready to begin the recruitment, enrollment, and dosing processes.
The clinical trial is titled “A phase1, open-label, dose-escalation, safety, pharmacokinetic and p
pharmacodynamic study of Kevetrin (Thioureidobutyronitrile) administered intravenously, in patients with advanced solid tumors.” Cellceutix has been advised to expect the first dosing of Kevetrin to be administered within approximately one week of activating the trial.
For additional information about Cellceutix, Kevetrin, and the company’s seven other drug compounds, visit the company’s website at www.cellceutix.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment